摘要
目的探讨DC/CIK细胞治疗对白细胞、红细胞、血小板和淋巴细胞的影响。方法对接受DC/CIK细胞治疗的63例癌症患者的血细胞资料进行回顾性分析。结果在第一疗程DC/CIK细胞治疗前和第二疗程DC/CIK细胞治疗后,63例患者的WBC、RBC、PT和LYM的数量变化无统计学意义(P>0.05)。结论 DC/CIK细胞治疗几乎没有血液学毒副反应,临床应用安全。
Objective To explore the impact of the DC/CIK（dendritic cell, DC/cytokine induced killer cell, CIK） cell therapy on white blood cell,red blood cell,platelet and lymphocyte. Methods A retrospective blood cell date analysis of 63 cases of cancer patients receiving DC/CIK cell therapy was done. Results The difference of the count of WBC,RBC,PT and LYM of 63 cancer patient was not statistically significant（P〉0.05）before and after 2 cycles of DC/CIK cells infusion. Conclusions DC/CIK cell therapy has few hematology toxicity. Clinical use of DC/CIK cell therapy is safe.
出处
《中国现代医生》
2015年第19期16-18,共3页
China Modern Doctor
基金
吴阶平医学基金(320.6750.12632)
